- Trials with a EudraCT protocol (7)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
7 result(s) found for: Hepacivirus.
Displaying page 1 of 1.
EudraCT Number: 2010-020371-22 | Sponsor Protocol Number: UMCN-AKF 10.04 | Start Date*: 2011-05-03 | |||||||||||
Sponsor Name:Radboud University Nijmegen Medical Centre | |||||||||||||
Full Title: Achieving appropriate exposuRe to RIBAvirin after a dose advise based on an abbreviated AUC of a first dose of ribavirin (ARRIBA) | |||||||||||||
Medical condition: chronic HCV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-005500-14 | Sponsor Protocol Number: MZ-ATRACTION/ML 20804 | Start Date*: 2007-09-05 | |||||||||||
Sponsor Name:Universitätsmedizin der Johannes-Gutenberg Universität Mainz | |||||||||||||
Full Title: A Randomized, Open-label, Multicenter, Efficacy and Safety Study Examining the Effects on Viral Kinetics of All-trans Retinoic Acid (Tretinoin) (VESANOID®)in Combination with PEG-IFN alfa 2a (PEGA... | |||||||||||||
Medical condition: chronic HCV infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012579-90 | Sponsor Protocol Number: 1220.40 | Start Date*: 2009-08-04 | |||||||||||||||||||||
Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG | |||||||||||||||||||||||
Full Title: Antiviral effect and safety of once daily BI 201335 NA in hepatitis C virus genotype 1 infected treatment-naïve patients for 12 or 24 weeks as combination therapy with pegylated interferon-α 2a and... | |||||||||||||||||||||||
Medical condition: chronic hepatitis C | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: DE (Completed) FR (Completed) AT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-000620-26 | Sponsor Protocol Number: MK-3682B-034 | Start Date*: 2016-11-03 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase II/III, Open-label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-3682B (MK-3682 + Grazoprevir + MK-8408 Fixed Dose Combination) in Subjects with Chronic H... | |||||||||||||
Medical condition: Chronic Hepatitis C Infected Patient | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003858-25 | Sponsor Protocol Number: MK-5172-052 | Start Date*: 2014-03-10 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp. a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection and Chronic Kidney D... | |||||||||||||
Medical condition: Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) ES (Completed) SE (Completed) EE (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000343-32 | Sponsor Protocol Number: 5172-062 | Start Date*: 2014-05-27 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., | |||||||||||||
Full Title: A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with Chronic HCV GT1, GT4, and GT6 Infection who are... | |||||||||||||
Medical condition: Hepatitis C | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) NL (Completed) GB (Completed) RO (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020444-36 | Sponsor Protocol Number: TMC435-TiDP16-C208 | Start Date*: 2011-02-14 | |||||||||||
Sponsor Name:Janssen R&D Ireland | |||||||||||||
Full Title: A Phase III, randomized, double-blind, placebo-controlled study to investigate the efficacy, safety and tolerability of TMC435 vs. placebo as part of a treatment regimen including peginterferon alf... | |||||||||||||
Medical condition: Hepatitis C Virus (HCV) in treatment naïve patients | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) IT (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
